Upgrades/Downgrades
Updated: 15-Oct-26 16:30 ET
| Upgrades | |||||
| Company | Ticker | Brokerage Firm | Ratings Change | Price Target | |
| Zions Bancorp | ZION | Robert W. Baird | Neutral » Outperform | $75 | |
| Walmart | WMT | Deutsche Bank | Hold » Buy | $136 | |
| Scotts Miracle-Gro | SMG | UBS | Neutral » Buy | $70 | |
| Quantinuum | QNT | Morgan Stanley | Equal-Weight » Overweight | $62 | |
| Lithium Americas | LAC | Canaccord Genuity | Hold » Speculative Buy | ||
| Fortrea | FTRE | Deutsche Bank | Hold » Buy | $25 | |
| Crocs | CROX | Barclays | Equal Weight » Overweight | $139 | |
| CEMEX S.A. | CX | Citigroup | Neutral » Buy | $12 | |
| Casey's General | CASY | RBC Capital Mkts | Sector Perform » Outperform | $825 | |
| CarMax | KMX | BofA Securities | Underperform » Buy | $65 | |
| Brighthouse Financial | BHF | JP Morgan | Underweight » Neutral | $55 | |
| BorgWarner | BWA | BofA Securities | Neutral » Buy | $85 | |
| Bank of America | BAC | Robert W. Baird | Neutral » Outperform | $62 | |
| Array Tech | ARRY | Mizuho | Neutral » Outperform | $5 | |
| ArcelorMittal | MT | JP Morgan | Neutral » Overweight | ||
| Texas Roadhouse | TXRH | Stephens | Equal-Weight » Overweight | $205 | |
|
|
|||||
| Downgrades | |||||
| Company | Ticker | Brokerage Firm | Ratings Change | Price Target | |
| Siemens AG | SIEGY | Jefferies | Buy » Hold | ||
| ZTO Express | ZTO | Goldman | Buy » Neutral | $22 | |
| Par Pacific | PARR | Goldman | Buy » Neutral | $94 | |
| Envista | NVST | Robert W. Baird | Outperform » Neutral | $26 | |
| Dauch | DCH | BofA Securities | Buy » Underperform | $5 | |
| Cirrus Logic | CRUS | KeyBanc Capital Markets | Overweight » Sector Weight | ||
| Align Tech | ALGN | Robert W. Baird | Outperform » Neutral | $162 | |
| Albertsons | ACI | Goldman | Buy » Neutral | $13 | |
| Albertsons | ACI | JP Morgan | Overweight » Neutral | $14 | |
| RXO, Inc. | RXO | Citizens | Mkt Outperform » Mkt Perform | ||
|
|
|||||
| Coverage Initiated | |||||
| Company | Ticker | Brokerage Firm | Ratings Change | Price Target | |
| Praxis Precision Medicines | PRAX | UBS | Buy | $706 | |
| NorthWestern | NWE | Jefferies | Buy | $85 | |
| York Space Systems | YSS | Piper Sandler | Neutral | $9 | |
| Wave Life Sciences | WVE | UBS | Buy | $11 | |
| Viper Energy Partners | VNOM | Scotiabank | Sector Outperform | $54 | |
| Viking Therapeutics | VKTX | UBS | Buy | $94 | |
| Versant | VSNT | Morgan Stanley | Equal-Weight | $38 | |
| Vail Resorts | MTN | Citizens | Mkt Perform | ||
| Ultragenyx Pharma | RARE | UBS | Neutral | $16 | |
| Suja Life | SUJA | Needham | Buy | ||
| Solid Biosciences | SLDB | UBS | Buy | $20 | |
| SM Energy | SM | Scotiabank | Sector Perform | $39 | |
| Sight Sciences | SGHT | H.C. Wainwright | Buy | $14 | |
| Redwire | RDW | Piper Sandler | Neutral | $11 | |
| Rapport Therapeutics | RAPP | UBS | Buy | $71 | |
| Rapport Therapeutics | RAPP | Wolfe Research | Outperform | $50 | |
| Permian Resources | PR | Scotiabank | Sector Outperform | $29 | |
| Ovid Therapeutics | OVID | Wolfe Research | Outperform | $5 | |
| Northern Oil & Gas | NOG | Scotiabank | Sector Perform | $27 | |
| Murphy Oil | MUR | Scotiabank | Sector Perform | $41 | |
| MGE Energy | MGEE | JP Morgan | Neutral | $76 | |
| Matador Resources | MTDR | Scotiabank | Sector Perform | $59 | |
| Magnolia Oil & Gas | MGY | Scotiabank | Sector Outperform | $31 | |
| Infinity Natural Resources | INR | Scotiabank | Sector Outperform | $17 | |
| Hemab Therapeutics Holdings | COAG | JP Morgan | Overweight | $70 | |
| HawkEye 360 | HAWK | Piper Sandler | Overweight | $22 | |
| Gulfport Energy | GPOR | Scotiabank | Sector Outperform | $217 | |
| Gold Fields | GFI | Goldman | Neutral | $38 | |
| First Financial Bankshares | FFIN | Raymond James | Mkt Perform | ||
| Establishment Labs | ESTA | Stifel | Buy | $85 | |
| EQT Corp. | EQT | Scotiabank | Sector Perform | $54 | |
| EOG Resources | EOG | Scotiabank | Sector Perform | $144 | |
| Eloxx Pharmaceuticals | ELOX | Cantor Fitzgerald | Overweight | ||
| Diamondback Energy | FANG | Scotiabank | Sector Outperform | $250 | |
| Devon Energy | DVN | Scotiabank | Sector Outperform | $61 | |
| CRISPR Therapeutics | CRSP | UBS | Neutral | $52 | |
| Crescent Energy | CRGY | Scotiabank | Sector Outperform | $18 | |
| CNX Resources | CNX | Scotiabank | Sector Perform | $34 | |
| Chord Energy | CHRD | Scotiabank | Sector Outperform | $192 | |
| CAMP4 Therapeutics | CAMP | Needham | Buy | $8 | |
| Bright Minds Biosciences | DRUG | Wolfe Research | Outperform | $150 | |
| Black Hills Corp | BKH | Jefferies | Buy | $87 | |
| APA Corp. | APA | Scotiabank | Sector Perform | $44 | |
| Antero Resources | AR | Scotiabank | Sector Outperform | $46 | |
| AngloGold Ashanti | AU | Goldman | Buy | $104 | |
| Enel Chile | ENIC | BofA Securities | Neutral | ||
| Harmony Biosciences | HRMY | Ladenburg Thalmann | Buy | $55 | |
| Infleqtion | INFQ | Morgan Stanley | Equal-Weight | $12 | |
| Xanadu Quantum Technologies Inc. | XNDU | Morgan Stanley | Equal-Weight | $3.75 | |
| Arcutis Biotherapeutics | ARQT | Cantor Fitzgerald | Overweight | $48 | |
|
|
|||||
| Coverage Resumed | |||||
| Company | Ticker | Brokerage Firm | Ratings Change | Price Target | |
| Ionis Pharma | IONS | UBS | Buy | $88 | |
| Alnylam Pharma | ALNY | UBS | Buy | $354 | |
| Arrowhead | ARWR | UBS | Buy | $109 | |
| BioMarin Pharmaceutical | BMRN | UBS | Buy | $88 | |
| Spectrum Brands | SPB | UBS | Buy | $97 | |
| Shift4 Payments | FOUR | BofA Securities | Neutral | $42 | |
| Netflix | NFLX | Jefferies | Buy | $85 | |
| Global Payments | GPN | BofA Securities | Buy | $114 | |
| Fiserv | FISV | BofA Securities | Underperform | $48 | |
| Fidelity Nat'l Info | FIS | BofA Securities | Buy | $42 | |
| Digital Turbine | APPS | Roth Capital | Buy | $19 | |
| Toast | TOST | BofA Securities | Buy | $40 | |
| PayPal | PYPL | BofA Securities | Underperform | ||
| Jack Henry | JKHY | BofA Securities | Neutral | $165 | |
|
|
|||||
| (a) Brokerage firm initiating coverage participated in underwriting the recent IPO. |
| (b) Brokerage firm resumes coverage. |
| (c) Brokerage firm participated in the secondary offering. |
| * This list of reiterations/target changes is not comprehensive. |